[SCHEDULE 13G/A] Avanos Medical, Inc. SEC Filing

Rhea-AI Filing Summary

On 06/30/2025, The Vanguard Group filed Amendment No. 10 to Schedule 13G reporting its ownership of Chemours Company (CC) common stock.

• Shares beneficially owned: 17,663,980
• Ownership percentage: 11.8 % of outstanding shares
• Voting power: 0 sole; 181,238 shared
• Dispositive power: 17,324,381 sole; 339,599 shared

Vanguard qualifies as an investment adviser under Rule 13d-1(b)(1)(ii)(E). The firm states the position is held in the ordinary course of business and not to influence control. Clients of Vanguard retain rights to dividends and sale proceeds.

Crossing the 10 % threshold makes Vanguard a significant institutional holder, potentially enhancing liquidity and investor confidence, although its near-zero sole voting power limits direct governance influence.

Positive

• 11.8 % beneficial ownership by The Vanguard Group demonstrates substantial institutional support for Chemours.

Negative

• Minimal sole voting power (0 shares) limits Vanguard’s ability to influence Chemours’ corporate governance.

Insights

Portfolio Manager

TL;DR: Vanguard’s 11.8 % stake signals institutional confidence; limited own voting power tempers governance impact.

The filing shows Vanguard controls 17.7 M Chemours shares, exceeding the 10 % reporting trigger. Large passive ownership can tighten float and support valuation multiples by demonstrating blue-chip fund interest. However, with no sole voting power and only 181 k shared votes, Vanguard’s ability to sway strategy is minimal, suggesting passive exposure rather than activism. Still, such a stake may attract additional institutional buyers and lower volatility, a modest positive for CC shareholders.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 11)

Avanos Medical Inc

(Name of Issuer)

Common Stock

(Title of Class of Securities)

05350V106

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 05350V106

1

Names of Reporting Persons

The Vanguard Group

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

PENNSYLVANIA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 118,440.00
7	Sole Dispositive Power 4,281,879.00
8	Shared Dispositive Power 183,017.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

4,464,896.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.65 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Avanos Medical Inc
(b)	Address of issuer's principal executive offices: 5405 Windward Parkway, Alpharetta, GA, 30004
Item 2.
(a)	Name of person filing: The Vanguard Group
(b)	Address or principal business office or, if none, residence: 100 Vanguard Blvd., Malvern, PA 19355
(c)	Citizenship: PA
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 05350V106
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 4464896
(b)	Percent of class: 9.65 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 118440
	(iii) Sole power to dispose or to direct the disposition of: 4281879
	(iv) Shared power to dispose or to direct the disposition of: 183017
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein. No one other person's interest in the securities reported herein is more than 5%.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

The Vanguard Group

Signature:	Ashley Grim
Name/Title:	Head of Global Fund Administration
Date:	07/29/2025

FAQ

How much of Chemours (CC) does The Vanguard Group own?

Vanguard reports 17,663,980 shares, representing 11.8 % of Chemours’ outstanding common stock.

What voting rights does Vanguard have over its Chemours shares?

Vanguard has 0 shares with sole voting power and 181,238 shares with shared voting power.

Under which rule was this Schedule 13G filed?

The filing was made under Rule 13d-1(b) as Vanguard is an investment adviser.

Is Vanguard’s stake intended to influence control of Chemours?

No. The certification states the shares are held in the ordinary course of business and not for the purpose of influencing control.

What is the effective date of the reported ownership?

The ownership information is as of 06/30/2025.